Data-driven, personalised marketing is the future for many industries, including pharma. And in the next few years, we will witness more unique strategies and tools that help companies optimise ...

Drug development is an expensive and high-risk process. The median cost per approved drug can reach up to $2.8 billion, ...

IPA primarily represents companies specializing in producing generic drugs, which are lower-cost versions of branded ...

An index of Indian pharmaceutical company shares slid 2% to its lowest level in seven months on Wednesday after U.S.

While they still trade at premium valuations, they have not created much wealth for shareholders in recent times. The age-old ...

Trump’s tariff threats have sent shockwaves through Indian pharma stocks, but analysts argue the real casualty could be the ...

NSE leading the pack among unlisted entities and several others like Dream11 and Zerodha making significant contributions to ...

India currently imposes a 10% tariff on medicines imported from US. If Donald Trump decides to increase the tariff on Indian ...

Vishal Manchanda highlights the potential challenges the pharmaceutical sector may face in FY27 due to reliance on key drugs ...

Elara sees the ongoing weakness as an opportunity to buy into the pharma space, as it expects robust earnings growth ahead at ...

Nifty Pharma fell as much as 3.19% on Wednesday, led by the decline in Abbott Laboratories, Lupin and Ajanta Pharma.

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of ...